Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2020

View Archived Issues

Protagonist and Janssen select new oral peptide IL-23 receptor antagonist candidates

Updated preclinical data presented for psychedelic molecule FT-104

FDA clears IND application for phase I study of CORVax12 vaccine candidate for COVID-19

Promising topline data presented from phase II study of BPN-14770 in fragile X syndrome

Enanta Pharmaceuticals divulges new antivirals

Rottapharm Biotech discloses new DDR2 inhibitors

Peloton Therapeutics identifies RBM39 degradation inducers

Sichuan Kelun-Biotech Biopharmaceutical synthesizes USP7 inhibitors

Azitra discovers recombinant microorganisms for treating atopic dermatitis

Ester prodrug of a mGlu2/3 receptor agonist shows improved oral bioavailability

Second-generation anti-HCV cyclophilin inhibitor with reduced immunosuppressive activity

FDA approves IND for phase I study of PD1-Vaxx in NSCLC

A novel inducer of fetal hemoglobin with improved PK and PD properties

Results from SPI2 trial do not support the use of high-dose biotin for treating progressive MS

Insights, strategies for stabilizing dystrophin

Angiotensin 1-7 as novel biomarker to detect transplant AKI in children

Epigenomics approach links neurodegeneration SNPs to genes, cells, mechanisms

First-in-class LDHA inhibitor CHK-336 for treating primary hyperoxaluria

dEF-3122 improves inflammation and fibrosis in liver and kidneys of NASH mice

PLVAP, a new biomarker for endothelial injury in diabetic nephropathy

E.U. approval for Tecentriq with Avastin for advanced or unresectable HCC

FDA clears initiation of phase III trial of itolizumab in COVID-19 patients with ARDS

Preclinical data presented for the PSMA analogue [47Sc]Sc-PSMA-D4

Senhwa submits IND for phase II trial of silmitasertib for severe COVID-19

FDA lifts clinical hold on Poseida's phase I study of P-PSMA-101 in metastatic CRPC

Neuraly receives IND clearance for phase IIb study of NLY-01 in Alzheimer's disease

CureVac reports interim phase I data with SARS-CoV-2 vaccine candidate CVnCoV

Regeneron pauses dosing in phase II trial of garetosmab for fibrodysplasia ossificans progressiva

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.